infectious disease Archives -

Shares in US biotech Verrica Pharma lost half their value today after the FDA declined to approve its

Third FDA rejection for Verrica’s molluscum contagiosum drug

https://pharmaphorum.com/news/third-fda-rejection-for-verricas-molluscum-contagiosum-drug/

Monkeypox cases are rising. Should we be worried?

Phil Taylor antiviral, Bavarian Nordic, infectious disease, monkeypox, SIGA technologies, Smallpox, vaccine, World Health Organisation 0 Comment

The World Health Organization has said the current outbreak of monkeypox is the largest ever recorded outside sub-Saharan

Monkeypox cases are rising. Should we be worried?

https://pharmaphorum.com/news/monkeypox-cases-are-rising-should-we-be-worried/

News/ News/ R&D

Moderna’s HIV vaccine prepped for trials in Africa

Phil Taylor HIV, infectious disease, Moderna, mRNA, vaccine 0 Comment

Moderna has joined forces with non-profit organisation IAVI on a third phase 1 trial of its candidate HIV

Moderna’s HIV vaccine prepped for trials in Africa

https://pharmaphorum.com/news/modernas-hiv-vaccine-prepped-for-trials-in-africa/

News/ News/ R&D

AZ, Sanofi build case for one-shot RSV antibody

Phil Taylor AstraZeneca, infectious disease, nirsevimab, paediatrics, respiratory syncytial virus, Sanofi 0 Comment

A pooled analysis of data for AstraZeneca and Sanofi’s respiratory syncytial virus (RSV) antibody nirsevimab has concluded that

AZ, Sanofi build case for one-shot RSV antibody

https://pharmaphorum.com/news/az-sanofi-build-case-for-one-shot-rsv-antibody/

News/ News/ R&D

Pfizer bulks up in RSV with $525m takeover of ReViral

Phil Taylor antiviral, infectious disease, M&A, paediatrics, Pfizer, respiratory syncytial virus, ReViral 0 Comment

Pfizer is looking to follow its vaccine/oral antiviral combination that has proved so profitable in COVID-19 with a

Pfizer bulks up in RSV with $525m takeover of ReViral

https://pharmaphorum.com/news/pfizer-bulks-up-in-rsv-with-525m-takeover-of-reviral/

News

Sandoz, Ares extend digital alliance on antimicrobial resistance

Phil Taylor antibiotic, antimicrobial resistance, Ares Genetics, generic, infectious disease, OpGen, Sandoz 0 Comment

Novartis’ generics unit Sandoz has moved on to the next stage of a collaboration with Ares Genetics, which

Sandoz, Ares extend digital alliance on antimicrobial resistance

https://pharmaphorum.com/news/sandoz-ares-extend-digital-alliance-on-antimicrobial-resistance/

News/ News/ R&D

Pharma-backed antibiotic fund makes first investments

Phil Taylor AMR Action Fund, antibiotic, antimicrobial resistance, financing, infectious disease 0 Comment

Two years after it was first proposed and a year after it officially launched, the pharma-backed AMR Action

Pharma-backed antibiotic fund makes first investments

https://pharmaphorum.com/news/pharma-backed-antibiotic-fund-makes-first-investments/

News/ News/ R&D

Moderna targets 15 pathogens in ‘global public health strategy’

Phil Taylor emerging markets, infectious disease, Moderna, mRNA 0 Comment

Moderna has unveiled plans to start clinical trials of mRNA-based vaccines for 15 infectious diseases that pose the

Moderna targets 15 pathogens in ‘global public health strategy’

https://pharmaphorum.com/news/moderna-targets-15-pathogens-in-global-public-health-strategy/

News/ News/ R&D

Pfizer’s seeks silver lining in failed C. diff vaccine trial

Phil Taylor C. diff infections, infectious disease, Pfizer, vaccine 0 Comment

Pfizer’s vaccine for Clostridium difficile (C. diff) looks like it may join a growing list of candidates that

Pfizer’s seeks silver lining in failed C. diff vaccine trial

https://pharmaphorum.com/news/pfizers-seeks-silver-lining-in-failed-c-diff-vaccine-trial/

Trending

infectious disease

Login